The cardiovascular benefits of GLP-1s and GIPs may be independent of improvements in glycemic control, and in part be driven by reduction in inflammation, a key driver of arterial plaque formation
Closing the GLP-1 Coverage Gap: Q&A with Susan Thomas Mike Hollan , Susan Thomas Key Takeaways Formulary decisions commonly restrict access to T2D and weight loss, creating coverage blind spots as GLP-1 trials mature across broader cardiometabolic and organ-protection indications
Many anti-obesity medication consumers still incorporate treats like ice cream, desserts, and even alcoholic beverages, but in smaller portions. Rather than prioritizing absolute sugar reduction, these consumers may place greater emphasis on the quality of the experience and ingredients, and they may be willing to pay more while enjoying a portion-controlled sweet treat or sip for meaningful moments of indulgence. Samyang sees the GLP-1 shift as a structural pivot for the whole category
Lets continue the conversation and grow together as a community of traders and analysts
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity